Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
70 hedge funds and large institutions have $409M invested in Audentes Therapeutics, Inc in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 9 reducing their positions, and 5 closing their positions.
311% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 9
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
50% more capital invested
Capital invested by funds: $272M → $409M (+$137M)
21% more funds holding
Funds holding: 58 → 70 (+12)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$20.6M |
| 2 |
PA
Perceptive Advisors
New York
|
+$11.2M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$10.2M |
| 4 |
BlackRock
New York
|
+$8.74M |
| 5 |
Jennison Associates
New York
|
+$8.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.07M |
| 2 |
VMI
VHCP Management II
New York
|
-$7.82M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.71M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.62M |
| 5 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$1.13M |
BOLD Hedge Fund Activity: Q2 2017 in Review
70 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q2 2017, worth a combined $409M — up 50% from $272M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new BOLD positions and 5 closed out — a net gain of 12 holders — while 37 added to existing stakes and 9 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $20.6M. The largest seller was RA Capital Management, exiting entirely with an estimated $9.07M sold.
- 70 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q2 2017, up from 58 in Q1 2017.
- Funds reported $409M of Audentes Therapeutics, Inc stock for Q2 2017, up 50% quarter-over-quarter.
- 17 funds opened new Audentes Therapeutics, Inc positions in Q2 2017 and 5 closed out, a net change of +12 holders.
- The largest Audentes Therapeutics, Inc buyer in Q2 2017 was Adage Capital Partners, an estimated $20.6M added.
- The largest Audentes Therapeutics, Inc seller in Q2 2017 was RA Capital Management, an estimated $9.07M sold.
Based on aggregated 13F filings for Q2 2017.